Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
Go back to Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
February 24, 2025 7:00 AM EST
ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)
FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)
GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025
Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular... More
February 24, 2025 6:00 AM EST
Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function
Data will be presented in five... More
